Form 8-K - Current report:
SEC Accession No. 0001558370-22-018990
Filing Date
2022-12-27
Accepted
2022-12-27 16:30:21
Documents
12
Period of Report
2022-12-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20221227x8k.htm   iXBRL 8-K 41323
  Complete submission text file 0001558370-22-018990.txt   162815

Data Files

Seq Description Document Type Size
2 EX-101.SCH plx-20221227.xsd EX-101.SCH 3257
3 EX-101.LAB plx-20221227_lab.xml EX-101.LAB 16018
4 EX-101.PRE plx-20221227_pre.xml EX-101.PRE 10763
6 EXTRACTED XBRL INSTANCE DOCUMENT plx-20221227x8k_htm.xml XML 4912
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 221490583
SIC: 2836 Biological Products, (No Diagnostic Substances)